Literature DB >> 2590613

Factors affecting free (unbound) lignocaine concentration in suspected acute myocardial infarction.

P A Routledge1, W W Stargel, A Barchowsky, G S Wagner, D G Shand.   

Abstract

1. Free plasma lignocaine concentrations were measured for up to 48 h after constant infusion of the drug in 41 subjects with suspected acute myocardial infarction. 2. The free plasma lignocaine clearance at 12 h was significantly and proportionately related to body weight and to the presence of mild (Killip Class II) heart failure, with an 18% reduction in free clearance in the latter condition. 3. The free plasma lignocaine was not related to sex, age or the presence of confirmed acute myocardial infarction, when corrected for the effects of body weight and presence of heart failure. 4. Free plasma lignocaine concentration 1 h after a fixed loading dose were also significantly related to body weight and presence of heart failure but not to sex, age or proven acute myocardial infarction. 5. The data indicate that correction of loading and maintenance infusion for body weight and presence of (even mild) heart failure should somewhat reduce variability in free (and presumably active) plasma lignocaine concentrations but that the free plasma lignocaine concentration at 12 h is most accurately predicted by measuring the free (and to a lesser extent total) plasma lignocaine concentration at 1 h.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2590613      PMCID: PMC1380021          DOI: 10.1111/j.1365-2125.1989.tb03547.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Pharmacokinetics of lidocaine after prolonged intravenous infusions in uncomplicated myocardial infarction.

Authors:  J LeLorier; D Grenon; Y Latour; G Caillé; G Dumont; A Brosseau; A Solignac
Journal:  Ann Intern Med       Date:  1977-12       Impact factor: 25.391

2.  Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.

Authors:  P D Thomson; K L Melmon; J A Richardson; K Cohn; W Steinbrunn; R Cudihee; M Rowland
Journal:  Ann Intern Med       Date:  1973-04       Impact factor: 25.391

3.  On the role of alpha 1-acid glycoprotein in lignocaine accumulation following myocardial infarction.

Authors:  A Barchowsky; D G Shand; W W Stargel; G S Wagner; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

4.  A comparison of methods of lidocaine administration in patients.

Authors:  L B Salzer; A B Weinrib; R J Marina; J J Lima
Journal:  Clin Pharmacol Ther       Date:  1981-05       Impact factor: 6.875

5.  Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction.

Authors:  P A Routledge; W W Stargel; G S Wagner; D G Shand
Journal:  Ann Intern Med       Date:  1980-11       Impact factor: 25.391

6.  Relationship between alpha 1-acid glycoprotein and lidocaine disposition in myocardial infarction.

Authors:  P A Routledge; D G Shand; A Barchowsky; G Wagner; W W Stargel
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

7.  Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure.

Authors:  L F Prescott; K K Adjepon-Yamoah; R G Talbot
Journal:  Br Med J       Date:  1976-04-17

8.  Impairment of lidocaine clearance in elderly male subjects.

Authors:  D R Abernethy; D J Greenblatt
Journal:  J Cardiovasc Pharmacol       Date:  1983 Nov-Dec       Impact factor: 3.105

9.  Control of lidocaine therapy: new perspectives.

Authors:  P A Routledge; W W Stargel; A Barchowsky; G S Wagner; D G Shand
Journal:  Ther Drug Monit       Date:  1982       Impact factor: 3.681

  9 in total
  1 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.